Literature DB >> 6264119

Mechanisms of expression of herpes simplex virus-common surface antigens in clonal cells of a herpes simplex virus type 2-transformed line.

K Okazaki, Y Ohnishi, N Yoshida, S Kimura.   

Abstract

Rabbit antiserum hyperimmune to herpes simplex virus type 1 was used to study the expression of herpes simplex virus type-common surface antigens (CSA) by indirect immunofluorescence tests in three representative cell clones isolated from a herpes simplex virus type 2-transformed hamster line, 155-4. These three clones showed different phenotypes with respect to CSA expression: (i) a CSA-positive type (clone (155-4-213), in which the antigens increased soon (5 h) after seeding at 37 degrees C, but not after treatment with actinomycin D; (ii) a CSA-inducible type (clone 155-4-03), in which the antigens increased after treatment with actinomycin D (2 micrograms/ml) for 20 h, but not after seeding only; and (iii) a CSA-negative type (clone 155-4-16), in which the antigens did not increase after seeding or after actinomycin D treatment. CSA expression in the CSA-positive type was inhibited by 2-deoxy-D-glucose, but not by puromycin, suggesting that the expression required glycosylation, but not active protein synthesis. CSA expression in this type was insensitive to the protease inhibitors antipain and p-nitrophenyl-p'-guanidinobenzoate. On the other hand, actinomycin D-induced CSA expression in the CSA-inducible type was inhibited by both 2-deoxy-D-glucose and puromycin, suggesting that the induced expression required both glycosylation and protein synthesis. CSA expression induced in this type was sensitive to the two protease inhibitors at concentrations having little effect on overall cellular metabolism or cell viability. These results indicate that CSA expressions in the CSA-positive type and the CSA-inducible type are enhanced by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6264119      PMCID: PMC171173     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  p-Nitrophenyl-p'-guanidinobenzoate HCl: a new active site titrant for trypsin.

Authors:  T Chase; E Shaw
Journal:  Biochem Biophys Res Commun       Date:  1967-11-30       Impact factor: 3.575

2.  Antipain, a new protease inhibitor isolated from actinomycetes.

Authors:  H Suda; T Aoyagi; M Hamada; T Takeuchi; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1972-04       Impact factor: 2.649

3.  Type-specific surface antigens of cells infected with herpes simplex virus (1 and 2).

Authors:  A J Nahmias; I DelBuono; K E Schneweis; D S Gordon; D Thies
Journal:  Proc Soc Exp Biol Med       Date:  1971-10

4.  Comparison of the esterase activities of trypsin, plasmin, and thrombin on guanidinobenzoate esters. Titration of the enzymes.

Authors:  T Chase; E Shaw
Journal:  Biochemistry       Date:  1969-05       Impact factor: 3.162

5.  Stereochemistry of intercalation: interaction of daunomycin with DNA.

Authors:  W J Pigram; W Fuller; L D Hamilton
Journal:  Nat New Biol       Date:  1972-01-05

6.  Effect of 2-deoxy-D-glucose on the multiplication of Semliki Forest virus and the reversal of the block by mannose.

Authors:  G Kaluza; M F Schmidt; C Scholtissek
Journal:  Virology       Date:  1973-07       Impact factor: 3.616

7.  The interaction of aminocridines with nucleic acids.

Authors:  A Blake; A R Peacocke
Journal:  Biopolymers       Date:  1968       Impact factor: 2.505

8.  Invasive tumors induced in rats with actinomycin D.

Authors:  D Svoboda; J Reddy; C Harris
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

9.  Labeling and other effects of actinomycin D on human chromosomes.

Authors:  C P Miles
Journal:  Proc Natl Acad Sci U S A       Date:  1970-03       Impact factor: 11.205

10.  Properties of hamster embryo fibroblasts transformed in vitro after exposure to ultraviolet-irradiated herpes simplex virus type 2.

Authors:  R Duff; F Rapp
Journal:  J Virol       Date:  1971-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.